Market Overview

UPDATE: Jefferies Raises PT on Questcor Pharmaceuticals on Strong Q4, Robust 2013 Outlook

Related QCOR
BioTime CEO Explains What Could Happen To Stem Cell Research And The Company Under A New Guard In Washington
Mallinckrodt Is No Valeant-Philidor Situation, Morgan Stanley Says

In a report published Wednesday, Jefferies reiterated its Buy rating on Questcor Pharmaceuticals (NASDAQ: QCOR), and raised its price target from $30.00 to $38.00.

Jefferies noted, “QCOR beat on the topline and EPS on strong Acthar sales despite seasonal MS softness. While mgmt. expects Q1 headwinds including continued MS softness, inventory draw-down and administrative/distribution changes, it reiterated overall Acthar growth with favorable reimbursement outlook.”

Questcor Pharmaceuticals closed on Tuesday at $32.66.

Latest Ratings for QCOR

May 2014MizuhoDowngradesBuyNeutral
May 2014PiperJaffrayDowngradesOverweightNeutral
Apr 2014JefferiesDowngradesBuyHold

View More Analyst Ratings for QCOR
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (QCOR)

View Comments and Join the Discussion!